ProfileGDS5678 / 1455973_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 63% 61% 61% 60% 60% 64% 64% 61% 60% 60% 62% 61% 68% 62% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 13.8027963
GSM967853U87-EV human glioblastoma xenograft - Control 23.6477561
GSM967854U87-EV human glioblastoma xenograft - Control 33.66161
GSM967855U87-EV human glioblastoma xenograft - Control 43.5643860
GSM967856U87-EV human glioblastoma xenograft - Control 53.5721560
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 13.9150864
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 23.900664
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 33.6565661
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 43.5973160
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 13.5999260
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 23.6770562
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 33.6468561
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 44.1229568
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 53.6832462